About: Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Creator	Liu, Jie Zhu, Yun Hao, Qinggang Li, Xiaolan Lu, Sheng Teng, Yirong Teng, Zhaowei Xu, Shuanglan Yang, Lirong Zeng, Yong Zhao, Dake
Source	MedRxiv
abstract	BACKGROUND Remdesivir, an inhibitor of viral RNA-dependent RNA polymerases, has been identified as a candidate for COVID-19 treatment. However, the therapeutic effect of remdesivir is controversial. METHODS We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for randomized controlled trials on the clinical efficacy of remdesivir. The main outcomes were discharge rate, mortality, and adverse events. This study is registered at INPLASY (INPLASY202060046). RESULTS Data of 1075 subjects showed that remdesivir significantly increased the discharge rate of patients with COVID-19 compared with the placebo (50.4% vs. 45.29%; relative risk [RR] 1.19 [95% confidence interval [CI], 1.05-1.34], I2 = 0.0%, P = 0.754). It also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI, 0.44-0.92], I2 = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects showed that remdesivir significantly decreased the occurrence of serious adverse events (RR 0.77 [95% CI, 0.63-0.94], I2 = 0.0%, P = 0.716). CONCLUSION Remdesivir is efficacious and safe for the treatment of COVID-19. TRIAL REGISTRATION NUMBER This study is registered at the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY202060046).
has issue date	2020-06-29(xsd:dateTime)
bibo:doi	10.1101/2020.06.22.20136531
has license	medrxiv
sha1sum (hex)	fabc71a7be3473e58b008ecac1c4794c876b6fa2
schema:url	https://doi.org/10.1101/2020.06.22.20136531
resource representing a document's title	Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
resource representing a document's body	covid:fabc71a7be3473e58b008ecac1c4794c876b6fa2#body_text
is schema:about of	named entity 'RNA' named entity 'COVID' named entity 'RNA-dependent RNA polymerases' named entity 'Remdesivir' named entity 'therapeutic effect' named entity 'Double-Blind, Placebo-Controlled' named entity 'COVID' named entity 'septic shock' named entity 'copyright holder' named entity 'College Station, TX' named entity 'remdesivir' named entity 'medRxiv' named entity 'STATA' named entity 'remdesivir' named entity 'study protocols' named entity 'deep vein thrombosis' named entity 'medRxiv' named entity 'RCTs' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'Remdesivir' named entity 'preprint' named entity 'June 29' named entity 'copyright holder' named entity 'medRxiv' named entity 'remdesivir' named entity 'preprint' named entity 'acute kidney injury' named entity 'SARS-CoV-2' named entity 'peer review' named entity '95% CI' named entity 'preprint' named entity 'copyright holder' named entity 'remdesivir' named entity 'pneumoviruses' named entity 'p-value' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'Wuhan' named entity 'copyright holder' named entity 'CC-BY-NC-ND 4.0' named entity 'cardiac arrest' named entity 'coronavirus' named entity 'adverse events' named entity 'anemia' named entity 'copyright holder' named entity 'lower respiratory' named entity 'cardiac arrest' named entity 'medRxiv' named entity 'disease symptoms' named entity 'Remdesivir' named entity 'CC-BY-NC-ND 4.0' named entity 'remdesivir' named entity 'remdesivir' named entity 'preprint' named entity 'preprint' named entity 'remdesivir' named entity 'Meta-analysis' named entity 'CC-BY-NC-ND 4.0' named entity 'preprint' named entity '1.06' named entity 'medRxiv' named entity 'COVID' named entity 'high-quality' named entity 'pulmonary embolism' named entity 'viral load' named entity 'morbidity' named entity 'mortality risk' named entity 'antiviral' named entity 'virus' named entity 'global pandemic' named entity 'medRxiv' named entity 'COVID-19' named entity 'preprint' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software